211 related articles for article (PubMed ID: 9205021)
1. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Mehra MR; Ventura HO; Kapoor C; Stapleton DD; Zimmerman D; Smart FW
Am J Cardiol; 1997 Jul; 80(1):61-4. PubMed ID: 9205021
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group.
Karlsberg RP; DeWood MA; DeMaria AN; Berk MR; Lasher KP
Clin Cardiol; 1996 Jan; 19(1):21-30. PubMed ID: 8903534
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors.
Milfred-LaForest SK; Shubert J; Mendoza B; Flores I; Eisen HJ; Piña IL
Am J Cardiol; 1999 Oct; 84(8):894-9. PubMed ID: 10532506
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents.
Tisdale JE; Patel R; Webb CR; Borzak S; Zarowitz BJ
Prog Cardiovasc Dis; 1995; 38(2):167-80. PubMed ID: 7568905
[TBL] [Abstract][Full Text] [Related]
5. [Additive effects of milrinone and dobutamine in severe heart failure].
Meissner A; Herrmann G; Gerdesmeyer L; Simon R
Z Kardiol; 1992 May; 81(5):266-71. PubMed ID: 1621407
[TBL] [Abstract][Full Text] [Related]
6. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
Colucci WS; Wright RF; Jaski BE; Fifer MA; Braunwald E
Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
[TBL] [Abstract][Full Text] [Related]
7. Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure.
Colucci WS
Am J Cardiol; 1989 Jan; 63(2):17A-22A. PubMed ID: 2909993
[TBL] [Abstract][Full Text] [Related]
8. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
Packer M; Carver JR; Rodeheffer RJ; Ivanhoe RJ; DiBianco R; Zeldis SM; Hendrix GH; Bommer WJ; Elkayam U; Kukin ML
N Engl J Med; 1991 Nov; 325(21):1468-75. PubMed ID: 1944425
[TBL] [Abstract][Full Text] [Related]
9. Outpatient parenteral inotropic therapy for advanced heart failure.
Young JB; Moen EK
J Heart Lung Transplant; 2000 Aug; 19(8 Suppl):S49-57. PubMed ID: 11016488
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial.
Aranda JM; Schofield RS; Pauly DF; Cleeton TS; Walker TC; Monroe VS; Leach D; Lopez LM; Hill JA
Am Heart J; 2003 Feb; 145(2):324-9. PubMed ID: 12595851
[TBL] [Abstract][Full Text] [Related]
11. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
Pflugfelder PW; O'Neill BJ; Ogilvie RI; Beanlands DS; Tanser PH; Tihal H; Mizgala HF; Fitchett DH; Kostuk WJ
Can J Cardiol; 1991; 7(1):5-10. PubMed ID: 2025794
[TBL] [Abstract][Full Text] [Related]
12. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
Domínguez de Rozas JM; Guindo Soldevila J; Rodríguez Font E; Martínez Vílchez R
Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy.
Biddle TL; Benotti JR; Creager MA; Faxon DP; Firth BG; Fitzpatrick PG; Konstam MA; Krebs C; Walton L; Kershner RP
Am J Cardiol; 1987 Jun; 59(15):1345-50. PubMed ID: 3591689
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients with severe congestive heart failure treated with oral milrinone.
Baim DS; Colucci WS; Monrad ES; Smith HS; Wright RF; Lanoue A; Gauthier DF; Ransil BJ; Grossman W; Braunwald E
J Am Coll Cardiol; 1986 Mar; 7(3):661-70. PubMed ID: 3950244
[TBL] [Abstract][Full Text] [Related]
16. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
Meissner A; Schmelzle T; Simon R
Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
[TBL] [Abstract][Full Text] [Related]
17. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade.
Travill CM; Pugh S; Noble MI
Clin Ther; 1994; 16(5):783-92. PubMed ID: 7859237
[TBL] [Abstract][Full Text] [Related]
18. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates.
Canver CC; Chanda J
Ann Thorac Surg; 2000 Jun; 69(6):1823-6. PubMed ID: 10892930
[TBL] [Abstract][Full Text] [Related]
19. Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition.
Klocke RK; Mager G; Kux A; Höpp HW; Hilger HH
Am Heart J; 1991 Jun; 121(6 Pt 2):1965-73. PubMed ID: 2035428
[TBL] [Abstract][Full Text] [Related]
20. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good.
Varriale P; Ramaprasad S
Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
